A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Etoposide (Primary) ; Etoposide (Primary) ; Pralatrexate (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Melphalan; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2013 Preliminary results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Jun 2012 New source identified and integrated (Mayo Clinic).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top